Company intelligence / Profile preview

Pheast Therapeutics

Palo Alto, CA, United Statespheast.com ↗

Ownership: Private
Employees: ~35
Development stage: Preclinical

Overview

Pheast’s lead asset, PHST001, an anti-CD24 monoclonal antibody designed to block a key macrophage checkpoint, has entered a multicenter Phase 1 clinical trial for advanced solid tumors. Preclinical data showed that PHST001 promoted phagocytosis of cancer cells by macrophages and led to significant tumor shrinkage in animal models. The company’s approach aims to overcome immune evasion by targeting the CD24–Siglec‑10 axis on tumor cells.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Macrophage checkpoint inhibitors
Industry: Biotech

Drug pipeline

2 assets

PHST001

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Pheast Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pheast Therapeutics.